//

Imclone Systems Inc.

Posted Mon, 09/14/2009 - 12:41 by Zefu

Imclone Systems Inc.

180 Varick Street
New York, NY 10014
USA
Phone: (212) 645-1405
Fax: (212) 645-2054
Email: ir@imclone.com
Web Site: http://www.imclone.com/

A. Company Profile

ImClone Systems Incorporated (Nasdaq: IMCL) is a biopharmaceutical company dedicated to developing breakthrough biologic medicines in the area of oncology. The Company has utilized the many advances made in the fields of molecular biology, oncology, genomics and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and development.

B. Products

Product Pipelines
Product Indication Clinical Status
Erbitux Colorectal cancer and head and neck cancer Market
IMC-3G3 Breast, ovarian, and prostate cancers Phase I
IMC-11F8 Various tumors Phase II
IMC-1121b Various tumors Phase II
IMC-18F1 Breast cancer Phase I
IMC-A12 Various tumors Phase II

1. Erbitux

Erbitux (cetuximab or C225) is a chimeric monoclonal antibody that has been designed to bind exclusively to the epidermal growth factor receptor (EGFR). When bound to the receptor, it is intended to block the ability of certain growth factors (EGF & TGF-alpha) to bind and signal the cell to promote tumor cell growth, survival and progression. Erbitux is being developed in the United States by ImClone Systems and Bristol-Myers Squibb.

2. IMC-3G3

IMC-3G3 is a PDGFR inhibitor

3. IMC-11F8

IMC-11F8 is an EGFR inhibitor

4. IMC-1121b

IMC-1121b is a VEGFR-2/KDR inhibitor.

5. IMC-A12

IMC-A12 is an IGF-1R inhibitor.